Shire announces changes at the top

Share this article:
Shire CEO Matthew Emmens
Shire CEO Matthew Emmens

Shire announced succession plans today under which Dr. James Cavanaugh will step down as chairman in June and CEO Matthew Emmens will succeed him as non-executive chairman.

Also next June, Angus Russell will take over for Emmens as CEO and David Kappler will become deputy chairman while continuing in his existing role as senior independent director.
 
The changes will be made official at Shire's annual general meeting to be held next summer.

Emmens joined Shire in 2003. His successor Russell has been CFO since 1999 and has 27 years experience in the pharmaceutical industry including working for ICI, Zeneca and AstraZeneca in finance, strategy and marketing. Throughout his time with Shire, Russell has been a lead member of the Shire Management Committee that devised and implemented Shire's long-term focused business strategy. Shire will now work to identify a replacement CFO in order to ensure an orderly succession, the company said in a statement.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...